Theranostics Studies in Precision Medicine

From human blood (lymphocytes). The DNA can be extracted at LBioMiT (preferential) or we can perform the analysis in a DNA sample extracted previously and outside the laboratory.

There is a huge variety of pharmacological treatment in several medical specialties. However, there is variability in the therapeutic efficacy and adverse secondary effects are frequent, as adverse reactions to medications affect about 2,000,000 people every year. This has a direct impact in morbility, mortality and leads to an increase in the spenditure in medical costs.

Laboratory precision medicine, through analysis of the pharmacogenomics/pharmacogenetics profile, allows to:

• Adjust to the appropriate drug dose, achieving the best possible response;
• Prevents adverse effects.

The CYP2D6 (OMIM #124030) enzyme metabolizes 25-30% of the most frequently prescribed drugs.

LBioMiT has the genotyping of the CYP2C19 in final stage of implementation, also performed in real-time PCR, analyzing relevant polymorphisms and copy number of this gene.

It is possible to perform studies in other pharmacogenetics-connected genes by Whole exome/Specific nDNA study.

The development and implementation of genotyping for other genes by real-time PCR can be explored.